RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Dechra Pharmaceuticals Stock

Dechra Pharmaceuticals EBIT 2024

Dechra Pharmaceuticals EBIT

157.7 M GBP

Ticker

DPH.L

ISIN

GB0009633180

WKN

578968

In 2024, Dechra Pharmaceuticals's EBIT was 157.7 M GBP, a 533.33% increase from the 24.9 M GBP EBIT recorded in the previous year.

The Dechra Pharmaceuticals EBIT history

YEAREBIT (undefined GBP)
2028e-
2027e256.68
2026e192.99
2025e184.46
2024e157.7
202324.9
2022101.5
202187
202058.7
201950.6
201845.1
201740.91
201632.71
201526.48
201425.6
201320.9
201225.7
201122.9
201021.2
200917.7
200814.1
200713.8
200612.3
200510.4
20048.6

Dechra Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Dechra Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Dechra Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Dechra Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Dechra Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Dechra Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Dechra Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Dechra Pharmaceuticals’s growth potential.

Dechra Pharmaceuticals Revenue, EBIT and net profit per share

DateDechra Pharmaceuticals RevenueDechra Pharmaceuticals EBITDechra Pharmaceuticals Net Income
2028e1.07 B undefined0 undefined230.69 M undefined
2027e1 B undefined256.68 M undefined179.94 M undefined
2026e982.83 M undefined192.99 M undefined203.81 M undefined
2025e926.35 M undefined184.46 M undefined166.98 M undefined
2024e851.26 M undefined157.7 M undefined147.77 M undefined
2023761.5 M undefined24.9 M undefined-27.9 M undefined
2022681.8 M undefined101.5 M undefined58.2 M undefined
2021608 M undefined87 M undefined55.5 M undefined
2020515.1 M undefined58.7 M undefined33.9 M undefined
2019481.8 M undefined50.6 M undefined30.9 M undefined
2018407.1 M undefined45.1 M undefined36.1 M undefined
2017359.28 M undefined40.91 M undefined26.11 M undefined
2016247.56 M undefined32.71 M undefined12.67 M undefined
2015203.48 M undefined26.48 M undefined19.46 M undefined
2014193.6 M undefined25.6 M undefined59 M undefined
2013189.2 M undefined20.9 M undefined17.9 M undefined
2012426 M undefined25.7 M undefined11.7 M undefined
2011389.2 M undefined22.9 M undefined14.1 M undefined
2010369.4 M undefined21.2 M undefined13.2 M undefined
2009350 M undefined17.7 M undefined11.3 M undefined
2008304.4 M undefined14.1 M undefined8.3 M undefined
2007253.8 M undefined13.8 M undefined8.8 M undefined
2006232.5 M undefined12.3 M undefined7.6 M undefined
2005208.2 M undefined10.4 M undefined6.3 M undefined
2004186.8 M undefined8.6 M undefined5.1 M undefined

Dechra Pharmaceuticals stock margins

The Dechra Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Dechra Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Dechra Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Dechra Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Dechra Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Dechra Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Dechra Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Dechra Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Dechra Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Dechra Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Dechra Pharmaceuticals Margin History

Dechra Pharmaceuticals Gross marginDechra Pharmaceuticals Profit marginDechra Pharmaceuticals EBIT marginDechra Pharmaceuticals Profit margin
2028e56.41 %0 %21.48 %
2027e56.41 %25.59 %17.94 %
2026e56.41 %19.64 %20.74 %
2025e56.41 %19.91 %18.03 %
2024e56.41 %18.53 %17.36 %
202356.41 %3.27 %-3.66 %
202256.51 %14.89 %8.54 %
202156.89 %14.31 %9.13 %
202056.61 %11.4 %6.58 %
201957.74 %10.5 %6.41 %
201855.88 %11.08 %8.87 %
201754.54 %11.39 %7.27 %
201655.95 %13.21 %5.12 %
201557.08 %13.01 %9.56 %
201455.63 %13.22 %30.48 %
201353.22 %11.05 %9.46 %
201223.31 %6.03 %2.75 %
201122.71 %5.88 %3.62 %
201021.82 %5.74 %3.57 %
200921.06 %5.06 %3.23 %
200817.61 %4.63 %2.73 %
200714.54 %5.44 %3.47 %
200614.32 %5.29 %3.27 %
200514.27 %5 %3.03 %
200413.6 %4.6 %2.73 %

Dechra Pharmaceuticals Aktienanalyse

What does Dechra Pharmaceuticals do?

Dechra Pharmaceuticals PLC is a British company specializing in animal medicine. It was founded in 1997 and has experienced remarkable growth since then. Dechra is listed on the London Stock Exchange and has its headquarters in Northwich, Cheshire, UK. Dechra builds its business models on a broad portfolio of products and services. The company is primarily focused on the development and sale of pharmaceuticals and diagnostics tailored to the needs of veterinarians and pet owners. The company has an extensive range of animal medicines, divided into categories such as antibiotics, painkillers, and anti-inflammatory drugs. Dechra operates three major business segments that drive its growth: the veterinary medicines business, the diagnostics business, and the specialty pharma business. The veterinary medicines business is the core of Dechra's operations. Here, the company produces products that can be used on livestock and companion animals. Dechra dominates the animal medicine market in Europe and has also established itself in the field of animal health in the US. The diagnostics business is another important segment that focuses on diagnostics and tests to quickly and effectively diagnose animal diseases. These products are primarily sold to veterinarians and veterinary laboratories. Dechra's specialty pharma business focuses on the production of specialty drugs tailored to a specific animal species or a specific disease that affects rarer species. Producing such medications generally requires higher expertise and also results in higher profitability due to typically lower competition. In recent years, Dechra has accelerated its presence and growth through targeted acquisitions. These acquisitions have expanded both Dechra's portfolio and geographic reach. In 2014, Dechra acquired US-based Genera N.A., a specialized pharmaceutical company producing animal medicines. With the acquisition of Genera, Dechra was able to strengthen its presence in the US animal medicine market. The company has also made acquisitions in Europe, such as the acquisition of Eurovet Animal Health in 2020. Eurovet is a Netherlands-based company specializing in animal health products and covers important market regions in Europe. The acquisition of Eurovet has allowed Dechra to strengthen its presence in Germany and Scandinavia. In summary, Dechra Pharmaceuticals PLC is one of the leading companies in the animal medicine industry. The company has maintained its reputation by creating innovative products and services based on the highest manufacturing and operational standards. The company is committed to continuing to provide value to veterinarians and pet owners while improving the health and well-being of animals. Dechra Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Dechra Pharmaceuticals's EBIT

Dechra Pharmaceuticals's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Dechra Pharmaceuticals's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Dechra Pharmaceuticals's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Dechra Pharmaceuticals’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Dechra Pharmaceuticals stock

How much did Dechra Pharmaceuticals achieve in EBIT for the current year?

In the current year, Dechra Pharmaceuticals has achieved an EBIT of 157.7 M GBP.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Dechra Pharmaceuticals.

How has the EBIT of Dechra Pharmaceuticals developed in recent years?

The EBIT of Dechra Pharmaceuticals has increased by 533.333% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Dechra Pharmaceuticals?

The EBIT of Dechra Pharmaceuticals is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Dechra Pharmaceuticals pay?

Over the past 12 months, Dechra Pharmaceuticals paid a dividend of 0.25 GBP . This corresponds to a dividend yield of about 0.65 %. For the coming 12 months, Dechra Pharmaceuticals is expected to pay a dividend of 0.25 GBP.

What is the dividend yield of Dechra Pharmaceuticals?

The current dividend yield of Dechra Pharmaceuticals is 0.65 %.

When does Dechra Pharmaceuticals pay dividends?

Dechra Pharmaceuticals pays a quarterly dividend. This is distributed in the months of November, April, November, April.

How secure is the dividend of Dechra Pharmaceuticals?

Dechra Pharmaceuticals paid dividends every year for the past 25 years.

What is the dividend of Dechra Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0.25 GBP are expected. This corresponds to a dividend yield of 0.65 %.

In which sector is Dechra Pharmaceuticals located?

Dechra Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Dechra Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Dechra Pharmaceuticals from 4/13/2023 amounting to 0.125 GBP, you needed to have the stock in your portfolio before the ex-date on 3/9/2023.

When did Dechra Pharmaceuticals pay the last dividend?

The last dividend was paid out on 4/13/2023.

What was the dividend of Dechra Pharmaceuticals in the year 2023?

In the year 2023, Dechra Pharmaceuticals distributed 0.449 GBP as dividends.

In which currency does Dechra Pharmaceuticals pay out the dividend?

The dividends of Dechra Pharmaceuticals are distributed in GBP.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Dechra Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Dechra Pharmaceuticals

Our stock analysis for Dechra Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dechra Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.